Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Project Information

STROBE

Grant agreement ID: 672768

DOI 10.3030/672768

Project closed

EC signature date 10 April 2015

Start date 1 May 2015

End date 31 October 2015

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

CRITICAL PHARMACEUTICALS LIMITED
United Kingdom

Objective

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › chemical sciences › polymer sciences
• medical and health sciences › clinical medicine › ophthalmology
• medical and health sciences › medical biotechnology › cells technologies › stem cells

Programme(s)

• H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Topic(s)

• NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2014

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

CRITICAL PHARMACEUTICALS LIMITED

• Net EU contribution: € 50 000,00
• Address: BIOCITY NOTTINGHAM - PENNYFOOT STREET ; NG1 1GF NOTTINGHAM ; United Kingdom
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Region: East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00